Wellenreiten – 12 Monate COVID-19 im Maximalversorger

 

 Permissions and Reprints

Zusammenfassung

Einleitung Mit weit mehr als 1400 stationär behandelten COVID-19-Patienten ist die Universitätsmedizin Essen der größte COVID-19-Versorger der Region Rhein-Ruhr. Wir präsentieren die Daten unserer Patienten aus den ersten 12 Monaten der Pandemie und die hieraus entstandenen praktischen Konzepte.

Methode Retrospektive Analyse aller 1396 stationären COVID-19-Patienten, die zwischen dem 1. März 2020 und 28. Februar 2021 versorgt wurden, im Hinblick auf Komorbiditäten, Überleben und Komplikationen im Verlauf. Es erfolgte ein Gruppenvergleich zwischen Patienten auf Normalstation und Überwachungs-/ Intensivstation.

Ergebnisse Bei einer Gesamtmortalität von 19,8 % (277/1396) starben 10,6 % (93/877) der Patienten auf Normalstation und 35,5 % (184/519) der Patienten auf Intensiv- und Überwachungsstationen im klinischen Verlauf. Hierbei waren ein Alter über 60 Jahre, Adipositas, maschinelle Beatmung, NO-Therapie, ECMO-Therapie sowie akutes Nierenversagen und Apoplex im Therapieverlauf unabhängige Prädiktoren für Mortalität.

Fazit Die Mortalität unseres Kollektivs auf Normal- bzw. Intensivstationen liegt im Rahmen international publizierter Daten. Sowohl die hohe Rate von Komplikationen bei schwerem Verlauf als auch die große Bedeutung einfacher Komorbiditäten kann eindrücklich gezeigt werden. Das mittlere Alter der Patienten ist mit 60 Jahren auf Normalstation und 63 Jahren auf Intensivstationen überraschend niedrig. Maximaler Patienten- und Personalschutz, eine rasche und effektive Teststrategie im Rahmen der primären Triage, standardisierte Abläufe von der Notaufnahme bis zur Intensivstation sowie eine dynamische tagesaktuelle Anpassung der Ressourcen können eine hohe Versorgungsqualität, auch während der Pandemie, sichern.

Abstract

Introduction With more than 1400 COVID-19 inpatients, the university hospital of Essen is the main regional caregiver during COVID-19 pandemic. We present outcome data of our inpatients during the first 12 months of pandemic and our derived clinical care concepts.

Methods Retrospective analysis of all 1396 COVID-19 inpatients presenting between March, 1^st of 2020 and February, 28^th of 2021 for comorbidities, survival and complications. Group comparison between patients receiving standard care and those requiring intermediate/ intensive care.

Results Mortality rate of all inpatients was 19,8 % (277/ 1396), whereas 10.6 % (93/877) of the patients with standard care and 35.5 % (184/519) of those with intermediate/intensive care died during hospital stay. Age above 60 years, obesity, need for mechanical ventilation, nitric oxide therapy, ECMO and acute renal failure as well as stroke during the clinical course were independent predictors of mortality.

Conclusions The mortality of both patient groups ranges within the numbers published by other international groups. The vast impact of usual comorbidities could be observed as well as the high rate of complications in serious ill COVID-19 patients. The mean age of both patient groups was lower than expected (60 years standard care versus 63 years intermediate/ intensive care). A maximum of patient and staff protection measures, a fast and efficient testing strategy during primary triage, standardized concepts from emergency department to intensive care units and dynamic adjustment of resources to daily changing needs can ensure a high quality of care even during peak of pandemic.

Publication History

Article published online:
29 December 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 Jin X, Lian JS, Hu JH. et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020; 69: 1002-1009 DOI: 10.1136/gutjnl-2020-320926.
  CrossrefPubMedGoogle Scholar
• 2 Petrilli CM, Jones SA, Yang J. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369: m1966 DOI: 10.1136/bmj.m1966.
  CrossrefPubMedGoogle Scholar
• 3 Dennis JM, McGovern AP, Vollmer SJ. et al. Improving Survival of Critical Care Patients With Coronavirus Disease 2019 in England: A National Cohort Study, March to June 2020. Crit Care Med 2021; 49: 209-214 DOI: 10.1097/CCM.0000000000004747.
  CrossrefPubMedGoogle Scholar
• 4 Karagiannidis C, Mostert C, Hentschker C. et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med 2020; 8: 853-862 DOI: 10.1016/S2213-2600(20)30316-7.
  CrossrefPubMedGoogle Scholar
• 5 Arnold FW, Wiemken TL, Peyrani P. et al. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2013; 107: 1101-1111 DOI: 10.1016/j.rmed.2013.04.003.
  CrossrefPubMedGoogle Scholar
• 6 Verma AA, Hora T, Jung HY. et al. Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area. CMAJ 2021; 193: E410-E418 DOI: 10.1503/cmaj.202795.
  CrossrefPubMedGoogle Scholar
• 7 Ranucci M, Ballotta A, Di Dedda U. et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020; 18: 1747-1751 DOI: 10.1111/jth.14854.
  CrossrefPubMedGoogle Scholar
• 8 Helms J, Tacquard C, Severac F. et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46: 1089-1098 DOI: 10.1007/s00134-020-06062-x.
  CrossrefPubMedGoogle Scholar
• 9 Guan WJ, Ni ZY, Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382: 1708-1720 DOI: 10.1056/NEJMoa2002032.
  CrossrefPubMedGoogle Scholar
• 10 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-1242 DOI: 10.1001/jama.2020.2648.
  CrossrefPubMedGoogle Scholar
• 11 Jakob CEM, Borgmann S, Duygu F. et al. First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)". Infection 2021; 49: 63-73 DOI: 10.1007/s15010-020-01499-0.
  CrossrefPubMedGoogle Scholar
• 12 Gupta S, Hayek SS, Wang W. et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med 2020; 180: 1436-1447 DOI: 10.1001/jamainternmed.2020.3596.
  CrossrefPubMedGoogle Scholar
• 13 Fistera D, Pabst D, Hartl A. et al. Separating the wheat from the chaff-COVID-19 in a German emergency department: a case-control study. Int J Emerg Med 2020; 13: 44 DOI: 10.1186/s12245-020-00302-z.
  CrossrefPubMedGoogle Scholar
• 14 Dinnes J, Deeks JJ, Berhane S. et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2021; 3: CD013705 DOI: 10.1002/14651858.CD013705.pub2.
  CrossrefPubMedGoogle Scholar
• 15 Holzner C, Pabst D, Anastasiou OE. et al SARS-CoV-2 rapid antigen test: Fast-safe or dangerous? An analysis in the emergency department of an university hospital. Journal of Medical Virology n/a. DOI: 10.1002/jmv.27033.
  CrossrefPubMedGoogle Scholar
• 16 Fontana LM, Villamagna AH, Sikka MK. et al. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. Infect Control Hosp Epidemiol 2020; 1-10 DOI: 10.1017/ice.2020.1273.
  CrossrefPubMedGoogle Scholar
• 17 Avanzato VA, Matson MJ, Seifert SN. et al Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell 2020; 183: 1901-1912 e1909 DOI: 10.1016/j.cell.2020.10.049.
  CrossrefPubMedGoogle Scholar
• 18 Dhont S, Derom E, Van Braeckel E. et al. The pathophysiology of 'happy' hypoxemia in COVID-19. Respir Res 2020; 21: 198 DOI: 10.1186/s12931-020-01462-5.
  CrossrefPubMedGoogle Scholar
• 19 Roberts MB, Izzy S, Tahir Z. et al. COVID-19 in solid organ transplant recipients: Dynamics of disease progression and inflammatory markers in ICU and non-ICU admitted patients. Transpl Infect Dis 2020; 22: e13407 DOI: 10.1111/tid.13407.
  CrossrefPubMedGoogle Scholar
• 20 Korth J, Wilde B, Dolff S. et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol 2020; 128: 104437 DOI: 10.1016/j.jcv.2020.104437.
  CrossrefPubMedGoogle Scholar
• 21 Kluge S, Janssens U, Welte T. et al. [Recommendations for critically ill patients with COVID-19]. Med Klin Intensivmed Notfmed 2020; 115: 175-177 DOI: 10.1007/s00063-020-00674-3.
  CrossrefPubMedGoogle Scholar
• 22 Coppo A, Bellani G, Winterton D. et al. Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. Lancet Respir Med 2020; 8: 765-774 DOI: 10.1016/S2213-2600(20)30268-X.
  CrossrefPubMedGoogle Scholar
• 23 Mustafa AK, Alexander PJ, Joshi DJ. et al. Extracorporeal Membrane Oxygenation for Patients With COVID-19 in Severe Respiratory Failure. JAMA Surg 2020; 155: 990-992 DOI: 10.1001/jamasurg.2020.3950.
  CrossrefPubMedGoogle Scholar
• 24 Huang C, Huang L, Wang Y. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220-232 DOI: 10.1016/S0140-6736(20)32656-8.
  CrossrefPubMedGoogle Scholar
• 25 Lenzen-Schulte M. Der Lange Schatten. Dtsch Arztebl 2020; 117 (49) A-2416/B-2036
  PubMedGoogle Scholar